Sagimet Biosciences Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $2.0M | — | — |
| Research and development | $39.1M | $38.4M | $19.8M | $24.9M | — |
| Operating expenses | $56.9M | $54.5M | $32.7M | $31.1M | — |
| Operating income | -$56.9M | -$54.5M | -$30.7M | -$31.1M | — |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$51.0M | -$45.6M | -$27.9M | -$30.5M | — |
| Balance Sheet | |||||
| Cash and equivalents | $35.0M | $75.8M | $75.1M | $158,000 | — |
| Current assets | $116.4M | $152.8M | $96.6M | $32.8M | — |
| Total assets | $116.5M | $160.3M | $96.7M | $33.0M | — |
| Current liabilities | $5.1M | $4.5M | $5.7M | $5.3M | — |
| Total liabilities | — | — | $5.7M | $5.4M | — |
| Stockholders' equity | $111.4M | $155.8M | $91.1M | -$186.9M | -$158.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$45.6M | -$42.4M | -$23.8M | -$24.5M | — |
| Stock-based compensation | $6.4M | $5.3M | $5.0M | $1.9M | — |
Shares outstanding 61.8M · Free float 72.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.